非奈利酮用于心力衰竭及PREDICT-HFpEF模型评估风险:FINEARTS-HF二次分析
本研究为FINEARTS-HF随机临床试验的二次分析,旨在验证PREDICT-HFpEF模型在HFmrEF/HFpEF患者中的表现,并评估非奈利酮疗效是否随基线风险变化。
要点
- PREDICT-HFpEF模型在FINEARTS-HF人群中校准与区分度良好。
- 最高风险五分位患者复合终点风险约为最低五分位的8-10倍。
- 非奈利酮的相对获益在各风险五分位间一致,基线风险未改变疗效。
核心结论
- PREDICT-HFpEF模型在FINEARTS-HF试验中校准和区分度表现良好。
- 基线风险未改变非奈利酮的获益,各风险谱相对风险降低一致。
研究设计与样本
- FINEARTS-HF为3期随机临床试验,在37个国家653个中心开展。
- 纳入6001例40岁及以上、有症状且左心室射血分数≥40%的心衰患者,2020年9月至2023年1月随机。
- 干预为非奈利酮(滴定至20 mg或40 mg)或安慰剂。
- 计算PREDICT-HFpEF的3个风险评分,比较预测与观察结局,用Harrell C统计量评估模型表现。
主要发现
- 2年时心血管死亡或心衰住院、心血管死亡、全因死亡的C统计量分别为0.71(95%CI 0.69-0.72)、0.68(95%CI 0.66-0.71)、0.69(95%CI 0.67-0.71)。
- 最高风险五分位患者复合终点风险约为最低五分位的8-10倍。
临床怎么用
- PREDICT-HFpEF模型可用于HFmrEF/HFpEF患者的风险分层。
- 非奈利酮的获益不因基线风险高低而改变,各风险层均可考虑使用。
局限性
- 本研究为FINEARTS-HF试验的二次分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patients with heart failure (HF) and mildly reduced ejection fraction (HFmrEF) or preserved ejection fraction (HFpEF) have a spectrum of risk, and the effect of therapies may vary by risk. OBJECTIVES: To validate the Prognostic Models for Mortality and Morbidity in HFpEF (PREDICT-HFpEF) in the phase 3 randomized clinical trial Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients With Heart Failure (FINEARTS-HF) and to evaluate the effect of finerenone, compared with placebo, across the spectrum of risk in these patients. DESIGN, SETTING, AND PARTICIPANTS: The FINEARTS-HF trial was conducted across 653 sites in 37 countries. Participants were adults 40 years and older with symptomatic HF and left ventricular EF of 40% or greater randomized between September 2020 and January 2023. INTERVENTION: Finerenone (titrated to 20 mg or 40 mg) or placebo. MAIN OUTCOMES AND MEASURES: The 3 PREDICT-HFpEF risk scores for the composite outcome of cardiovascular death or HF hospitalization, cardiovascular death, and all-cause death, respectively, were calculated. Predicted risk was compared with observed outcomes. Model performance was assessed using the Harrell C statistic. The rates of the predicted outcomes (plus the composite of cardiovascular death and worsening HF events, which was the primary end point in the trial) were examined according to quintiles of risk score, as was the effect of finerenone according to risk quintiles. RESULTS: A total of 6001 patients (mean [SD] age, 72 [9.6] years; 3269 male [54.5%]) were randomized in the FINEARTS-HF trial. The C statistics for cardiovascular death or HF hospitalization, cardiovascular death, and all-cause death at 2 years were 0.71 (95% CI, 0.69-0.72), 0.68 (95% CI, 0.66-0.71), and 0.69 (95% CI, 0.67-0.71), respectively. The risk of the composite outcomes was approximately 8- to 10-fold higher in those in the highest compared with the lowest risk quintile. The relative risk reduction with finerenone compared with placebo was consistent across the spectrum of risk for all outcomes examined (eg, interaction P value for primary outcome = .24). CONCLUSIONS AND RELEVANCE: Results of the FINEARTS-HF randomized clinical trial demonstrate that the PREDICT-HFpEF models performed well in terms of calibration and discrimination. Baseline risk did not modify the benefit of finerenone. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04435626.
引用
- McDowell K, Docherty KF, Campbell RT, et al. Finerenone for Heart Failure and Risk Estimated by the PREDICT-HFpEF Model: A Secondary Analysis of FINEARTS-HF. JAMA Cardiol. 2025. PMID: 40042880. doi:10.1001/jamacardio.2025.0025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。